Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer.
Breast Cancer Res Treat
; 128(2): 347-56, 2011 Jul.
Article
em En
| MEDLINE
| ID: mdl-20730488
ABSTRACT
Trastuzumab (Herceptin(®)) is currently used as a treatment for patients whose breast tumors overexpress HER2/ErbB2. Trastuzumab-DM1 (T-DM1, trastuzumab emtansine) is designed to combine the clinical benefits of trastuzumab with a potent microtubule-disrupting drug, DM1 (a maytansine derivative). Currently T-DM1 is being tested in multiple clinical trials. The mechanisms of action for trastuzumab include inhibition of PI3K/AKT signaling pathway, inhibition of HER-2 shedding and Fcγ receptor mediated engagement of immune cells, which may result in antibody-dependent cellular cytotoxicity (ADCC). Here we report that T-DM1 retains the mechanisms of action of unconjugated trastuzumab and is active against lapatinib resistant cell lines and tumors.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Quinazolinas
/
Neoplasias da Mama
/
Imunotoxinas
/
Receptor ErbB-2
/
Resistencia a Medicamentos Antineoplásicos
/
Maitansina
/
Anticorpos Monoclonais
Limite:
Animals
/
Female
/
Humans
Idioma:
En
Ano de publicação:
2011
Tipo de documento:
Article